Cardiovascular actions of the kappa-agonist, U-50,488H, in the absence and presence of opioid receptor blockade.

1. The cardiovascular actions of U-50,488H, a kappa-receptor agonist, were studied in rat isolated perfused hearts, and in anaesthetized rats, over concentrations or doses generally above those required to produce kappa-receptor-mediated effects. 2. U-50,488H dose-dependently decreased left-ventricular peak systolic pressure and beating rate in vitro and reduced blood pressure and heart rate in vivo. 3. Over the concentration range of 1-30 microM in vitro, and the dose-range of 0.5-32 mumol kg-1 in vivo, U-50,488H prolonged the P-R, QRS and Q-T intervals of the ECG. 4. The effects of U-50,488H were not antagonized by an opioid receptor antagonist, naloxone (1 microM or 8 mumol kg-1). Similarly, the opioid receptor antagonist, MR 2266, at 8 mumol kg-1 did not significantly reduce the cardiovascular actions of U-50,488H in vivo. 5. The actions of U-50,488H on responses to electrical stimulation were also studied. Over the dose range of 0.5-32 mumol kg-1, U-50,488H altered thresholds and effective refractory period. It had a biphasic action on thresholds for induction of ventricular fibrillation. Thresholds were decreased at lower doses (0.5-4 mumol kg-1) but increased at higher doses (8-32 mumol kg-1). The effects of lower doses were blocked by naloxone. Effective refractory period and threshold pulse width only increased with dose. 6. In conclusion, U-50,488H at high concentration, had direct depressant actions on cardiac contractility, electrical excitability and the ECG. These depressant effects were not antagonized by the opioid receptor antagonists, naloxone and MR 2266, and probably do not involve opioid receptors. Furthermore, some of the observed effects were those expected to result from sodium channel blockade.

Antiarrhythmic effects of U-50,488H in rats subject to coronary artery occlusion.

The antiarrhythmic actions of low and high doses of U-50,488H, a selective kappa-receptor agonist, were examined in pentobarbitone-anaesthetized rats subjected to occlusion of the left anterior descending coronary artery. At a high dose (16 mumol/kg) U-50,488H reduced blood pressure, heart rate and prolonged the P-R and QRS intervals of the electrocardiogram. This dose reduced the incidence of ventricular arrhythmias produced by occlusion. The blood pressure, heart rate, ECG and antiarrhythmic actions of a high dose of U-50,488H were not antagonized by 8 mumol/kg naloxone, a dose which had no cardiovascular or ECG actions. Naloxone alone reduced arrhythmia incidence but to a lesser extent than U-50,488H. A low dose (0.2 mumol/kg) of U50,488H in the absence or presence of naloxone had no effect on arrhythmias. Thus, U-50,488H had antiarrhythmic actions at a high dose which were independent of opioid receptors.

Relationship between QaT and RR intervals in rats, guinea pigs, rabbits, and primates.

The ECG is routinely used in many species to monitor effects of drugs. While it is relatively easy to measure both PR and QRS, measurement of QT is complicated by the fact that this interval can change with heart rate. In order to compensate for variations in QT due to variations in heart rate, various correction factors have been used, including those of Bazett and Hodges. Such corrections were devised for humans and may have limited applicability in other species. We have systematically varied heart rate in anesthetized rats, guinea pigs, rabbits, and primates using procedures such as vagal stimulation, direct atrial stimulation, injection of cold saline and drugs, including anesthetics, and measured the resulting QT (as QaT and related measures). Over a wide range of heart rates we tested various formulas for their value in correcting for the variation in QT interval associated with changes in heart rate. In rats the "QT" interval did not change appreciably with heart rate. In the other species QaT intervals varied in the expected manner with heart rate in that they decreased with tachycardia and increased with bradycardia. Various formulas were tested for their utility in correcting measures of the QaT interval (QaTc) for changes in heart rate in guinea pigs, rabbits, and primates. In species other than rats, there was little difference between the various formulas in their ability to increase the precision of QaTc and the normality of its distribution, although the best correction is that derived from the regression (either linear, square root, or polynomial) equation relating RR and QaT.